IONS vs. MDGL, ALKS, FOLD, GERN, DVAX, UTHR, TEVA, BMRN, ALNY, and APLS
Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), Dynavax Technologies (DVAX), United Therapeutics (UTHR), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
Ionis Pharmaceuticals (NASDAQ:IONS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Ionis Pharmaceuticals and 10 mentions for Madrigal Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.87 beat Madrigal Pharmaceuticals' score of -0.29 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.
93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ionis Pharmaceuticals received 228 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 68.60% of users gave Madrigal Pharmaceuticals an outperform vote while only 60.16% of users gave Ionis Pharmaceuticals an outperform vote.
Ionis Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals presently has a consensus target price of $59.54, suggesting a potential upside of 57.55%. Madrigal Pharmaceuticals has a consensus target price of $345.09, suggesting a potential upside of 53.40%. Given Ionis Pharmaceuticals' higher possible upside, equities research analysts plainly believe Ionis Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.
Ionis Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -49.49%. Ionis Pharmaceuticals' return on equity of -107.64% beat Madrigal Pharmaceuticals' return on equity.
Summary
Ionis Pharmaceuticals beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Ionis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ionis Pharmaceuticals Competitors List
Related Companies and Tools
